AVKARE LLC - NEW AWARD FOR METFORMIN HYDROCHLORIDE (HCL) 24HR SUSTAINED ACTION (SA) TABLETS PERIOD IS DECEMBER 30, 2025 - DECEMBER 29, 2026 WITH FOUR ONE-YEAR OPTIONS.
Key Details
Description
NEW AWARD FOR METFORMIN HYDROCHLORIDE (HCL) 24HR SUSTAINED ACTION (SA) TABLETS PERIOD IS DECEMBER 30, 2025 - DECEMBER 29, 2026 WITH FOUR ONE-YEAR OPTIONS.
Context & Analysis
On Oct 30, 2025, Department of Veterans Affairs to AVKARE LLC for new award for metformin hydrochloride (hcl) 24hr sustained action (sa) tablets period is december 30, 2025 - december 29, 2026 with four one-year options.. The award is classified under NAICS 325412 — PHARMACEUTICAL PREPARATION MANUFACTURING and issued as a firm fixed price contract. Competition extent: full and open competition with 2 offers received. The procurement used a NO SET ASIDE USED. set-aside. This award is one of several similar procurements from Department of Veterans Affairs under NAICS 325412 — related awards are listed below.
Contractor Information
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
MCKESSON CORPORATION
$1.2B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
Stay Updated
Get notified about new opportunities matching your interests.